14.72
+0.59
+(4.18%)
At close: April 2 at 4:00:02 PM EDT
14.30
-0.42
(-2.85%)
Pre-Market: 8:57:19 AM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 6 |
| Avg. Estimate | 0.91 | 0.91 | 3.85 | 4.03 |
| Low Estimate | 0.86 | 0.79 | 3.66 | 3.7 |
| High Estimate | 0.97 | 0.97 | 4.23 | 4.32 |
| Year Ago EPS | 1.22 | 1.12 | 4.11 | 3.85 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 7 | 7 |
| Avg. Estimate | 1.53B | 1.56B | 6.29B | 6.36B |
| Low Estimate | 1.5B | 1.54B | 6.16B | 6.15B |
| High Estimate | 1.58B | 1.59B | 6.6B | 6.79B |
| Year Ago Sales | 1.62B | 1.61B | 6.4B | 6.29B |
| Sales Growth (year/est) | -5.48% | -3.23% | -1.77% | 1.07% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.93 | 1.08 | 0.9 | 0.87 |
| EPS Actual | 1.22 | 1.12 | 0.87 | 0.9 |
| Difference | 0.29 | 0.04 | -0.03 | 0.03 |
| Surprise % | 30.60% | 4.07% | -3.70% | 3.95% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0.91 | 0.91 | 3.85 | 4.03 |
| 7 Days Ago | 0.91 | 0.91 | 3.84 | 4.08 |
| 30 Days Ago | 0.9 | 0.9 | 3.89 | 4.14 |
| 60 Days Ago | 1.08 | 1.02 | 4.13 | 4.39 |
| 90 Days Ago | 1.02 | 0.99 | 4.15 | 4.37 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | 1 | 1 | 2 | 1 |
| Down Last 7 Days | 1 | 1 | 2 | 1 |
| Down Last 30 Days | 5 | 5 | 6 | 4 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| OGN | -25.10% | -18.89% | -6.22% | 4.55% |
| S&P 500 | 6.69% | 6.80% | 9.98% | 14.34% |
Upgrades & Downgrades
| Maintains | Barclays: Overweight to Overweight | 2/14/2025 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 2/14/2025 |
| Downgrade | JP Morgan: Neutral to Underweight | 9/6/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 5/6/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 5/3/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 4/29/2024 |
Related Tickers
MRK Merck & Co., Inc.
86.60
-0.60%
GSK GSK plc
37.64
-0.61%
BMY Bristol-Myers Squibb Company
59.60
+0.08%
SNY Sanofi
53.95
-0.72%
BIIB Biogen Inc.
131.32
-0.54%
AMGN Amgen Inc.
305.70
-0.40%
PFE Pfizer Inc.
24.70
+0.65%
NVS Novartis AG
110.77
+1.06%
AZN AstraZeneca PLC
72.22
-0.52%
GRFS Grifols, S.A.
7.49
+7.61%